Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE

Key Points

• Hennion & Walsh Asset Management more than doubled its uniQure stake in the second quarter, acquiring 73,566 additional shares for a total holding of 142,113 shares worth approximately $6.55 million.
• QURE shares opened at $46.42, with the stock up sharply from its 12-month low of $8.73. Institutional investors own 78.83% of the company, while insiders have sold about 388,229 shares worth $16.8 million over the past 90 days.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $65 average price target. However, uniQure missed quarterly EPS estimates, reporting a loss of $1.22 per share versus the expected $0.82 loss.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 107.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,113 shares of the biotechnology company's stock after purchasing an additional 73,566 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.23% of uniQure worth $6,546,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in QURE. Torren Management LLC purchased a new position in uniQure in the fourth quarter valued at about $28,000. IFP Advisors Inc purchased a new stake in shares of uniQure during the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth approximately $48,000. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the 3rd quarter worth approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company's stock valued at $72,000 after purchasing an additional 906 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Price Performance

QURE stock opened at $46.42 on Monday. The stock has a 50-day simple moving average of $39.41 and a two-hundred day simple moving average of $27.07. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The firm has a market capitalization of $3.22 billion, a PE ratio of -11.58 and a beta of 0.93. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the business posted ($0.69) earnings per share. On average, equities analysts predict that uniQure N.V. will post -3.74 EPS for the current fiscal year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 21,082 shares of the firm's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the transaction, the chief executive officer directly owned 519,227 shares of the company's stock, valued at $23,448,291.32. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the business's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares of the company's stock, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 388,229 shares of company stock valued at $16,817,099. 4.65% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

QURE has been the topic of a number of recent research reports. Royal Bank Of Canada upped their price target on uniQure from $35.00 to $65.00 and gave the company an "outperform" rating in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research report on Tuesday, May 5th. Wolfe Research upgraded shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 target price for the company in a research note on Wednesday, July 29th. HC Wainwright boosted their price target on shares of uniQure from $50.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Finally, Wells Fargo & Company upped their price target on shares of uniQure from $60.00 to $75.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.00.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source